Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a material event occurring on January 20, 2021. The Company, an emerging growth company incorporated in Delaware, announced the pricing of a public offering of its common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 33,333,350 shares of common stock.
- Public Offering Price: $6.00 per share.
- Price to Underwriters: $5.64 per share.
- Expected Net Proceeds: Approximately $187.3 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 5,000,002 additional shares at the public offering price, less discounts.
- Expected Closing Date: January 22, 2021, subject to customary conditions.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the Company's operations.
Material Changes
The primary material change is the execution of an underwriting agreement with Oppenheimer & Co. Inc. to raise capital. This represents a significant increase in the Company's equity capital base pending the closing of the transaction.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the completion, timing, and expected net proceeds of the offering. Management notes that actual results may differ materially due to:
- Market conditions.
- Satisfaction of customary closing conditions.
- The ongoing COVID-19 global pandemic.
Investors are directed to the "Risk Factors" section of the Company's Form 10-Q for the period ended September 30, 2020, for a comprehensive list of risks.
Key Facts for Investor Verification
- Verify the actual closing of the offering on or around January 22, 2021.
- Confirm the final net proceeds received after all expenses are deducted.
- Check if the underwriters exercised the 30-day over-allotment option for the additional 5,000,002 shares.
- Review the Company's subsequent filings to understand the intended use of the $187.3 million in proceeds.